<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
THERAPEUTIC ANTIBODIES INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class Securities)
88337M100
- --------------------------------------------------------------------------------
(CUSIP Number)
November 9, 1998
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-l(b)
[X] Rule 13d-l(c)
[ ] Rule 13d-l(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED
IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY
VALID OMB CONTROL NUMBER.
<PAGE> 2
CUSIP NO. 88337M100 13G PAGE 2 OF 4 PAGES
- --------------------------------------------------------------------------------
1 Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (Entities Only)
WestLB Panmure Limited
- --------------------------------------------------------------------------------
Check the Appropriate Box if a Member of a Group
2 (See Instructions)
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
United Kingdom
- --------------------------------------------------------------------------------
5 Sole Voting Power
4,374,444
-------------------------------------------------------------
Number of 6 Shared Voting Power
Shares
Beneficially
Owned by Not applicable.
Each Reporting -------------------------------------------------------------
Person With 7 Sole Dispositive Power
4,374,444
-------------------------------------------------------------
8 Shared Dispositive Power
Not applicable.
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
4,374,444
- --------------------------------------------------------------------------------
10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
(See Instructions)
- --------------------------------------------------------------------------------
11 Percent of Class Represented by Amount in Row (9)
8.4%
- --------------------------------------------------------------------------------
12 Type of Reporting Person (See Instructions)
co
- --------------------------------------------------------------------------------
<PAGE> 3
Item 1(a) Name of Issuer: Therapeutic Antibodies Inc.
Item 1(b) Address of Issuer's Principal Executive Offices: 1207 17th
Avenue South, Suite 103, Nashville, TN 37212
Item 2(a) Name of Person Filing: WestLB Panmure Limited
Item 2(b) Address of Principal Business Office or, if None, Residence:
New Broad Street House, 35 New Broad Street, London EC2M 1SQ
Item 2(c). Citizenship: United Kingdom
Item 2(d). Title of Class of Securities: Common Stock
Item 2(e). CUSIP Number: 88337M100
Item 3. Not applicable.
Item 4. Ownership.
(a) Amount beneficially owned: 4,374,444
(b) Percent of class: 8.4%
(c) Number of shares as to which such person has:
(1) Sole power to vote or to direct the vote -
4,374,444
(ii) Shared power to vote or to direct the vote - Not
applicable.
(iii) Sole power to dispose or to direct the
disposition of - 4,374,444
(iv) Shared power to dispose or to direct the
disposition of - Not applicable.
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
<PAGE> 4
Item 10. CERTIFICATION.
The following certification shall be included if the
statement is filed pursuant to Rule 13d-l(c):
"By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the
securities and were not acquired in connection with or as a
participant in any transaction having that purposes or effect."
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
January 6, 1999
----------------------------------------
(Date)
/s/ J.R. Openshaw
----------------------------------------
(Signature)
Director
----------------------------------------
(Name and Title)
The original statement shall be signed by each person on whose behalf
the statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Note. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for
other parties for whom copies are to be sent.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT
CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
